Key result
Esaxerenone therapy for 6 months significantly decreased left ventricular mass index (P=0.001) and systolic blood pressure (P=0.003) compared to the pretreatment period in patients with HFpEF and refractory hypertension.
Why the study?
Does esaxerenone improve left ventricular mass index in patients with heart failure with preserved ejection fraction and refractory hypertension?
Cohort (n=33)
Single-blind (outcome assessors)
No
Does esaxerenone improve left ventricular mass index in patients with heart failure with preserved ejection fraction and refractory hypertension?
p-value: p=0.001
Esaxerenone may promote cardiac reverse remodeling and reduce left ventricular mass index in patients with HFpEF and refractory hypertension.
Esaxerenone may have beneficial effects of reverse remodeling in patients with HFpEF when used to treat hypertension. Further studies are needed to understand which patient populations may see greater benefits with esaxerenone.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a cohort in Heart Failure with Preserved Ejection Fraction (HFpEF) and hypertension (n=33). Esaxerenone vs. Pretreatment period (self-controlled) was evaluated on Change in left ventricular mass index (LVMI) between pretreatment and on-treatment periods (p=0.001). Esaxerenone therapy for 6 months significantly decreased left ventricular mass index (P=0.001) and systolic blood pressure (P=0.003) compared to the pretreatment period in patients with HFpEF and refractory hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: